DDX3 not only promoted cell invasion in KRAS-mutated CRC cells (138), but also increased tumor aggressiveness and cetuximab resistance in KRAS-wild-type CRC, which was regulated by the YAP1/SIX2 axis (139). Here, KRAS is linked to colorectal carcinoma.